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Abstract
Background—The correlation of null alleles with human phenotypes can provide insight into 
gene function in humans. In individuals of African ancestry, we set out to identify null and 
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damaging missense variants, and test these variants for association with a range of cardiovascular 
phenotypes.
Methods and Results—We performed whole exome sequencing in 3,223 African American 
individuals from the Jackson Heart Study and found a total of 729,666 variant sites with minor 
allele frequency (MAF) < 5%, including 17,263 null variants and 49,929 missense variants 
predicted to be damaging by in silico algorithms. We tested null and damaging missense variants 
within each gene for association with 36 cardiovascular traits. We found three associations that 
met our pre-specified level of significance (α=1.1×10−7). Null and damaging missense variants in 
PCSK9 were associated with 36 mg/dl lower low density lipoprotein cholesterol (LDL-C) (p-
value=3×10−21). Three individuals in their 50s with complete PCSK9 deficiency (each compound 
heterozygote for PCSK9 p.Y142X and p.C679X) were identified, with one having a coronary 
artery calcification score in the 83rd-percentile despite a LDL-C of 32 mg/dl. A damaging 
missense variant in HBQ1 (p.G52A) was associated with a 2 pg/cell lower mean corpuscular 
hemoglobin (p-value=9×10−13) and rare damaging missense variants in VPS13A with higher red 
blood cell distribution width (p-value=9.9 × 10−8).
Conclusions—A limited number of null/damaging alleles with a large effect on cardiovascular 
traits were detectable in ~3,000 African American individuals.
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A compelling therapeutic target for lowering low-density lipoprotein cholesterol (LDL-C) 
emerged from human genetic studies - the proprotein convertase subtilisin/kexin type 9 gene 
(PCSK9)1. Null alleles (also termed loss-of-function [LoF] protein-coding sequence 
variants) in PCSK9 were identified in African Americans2 and shown to associate with 
lower plasma LDL-C levels2–4 as well as reduced risk for CHD (up to 88% reduction)5, 6. 
Based on this human genetic evidence as well as corroborating functional studies, several 
pharmaceutical companies have established drug development programs targeting PCSK97 
and two inhibitors have been approved for reducing LDL-C in individuals with heterozygous 
familial hypercholesterolemia and individuals with clinical atherosclerotic cardiovascular 
disease8, 9. Based on the PCSK9 example, it has been suggested that low-frequency or rare 
mutations of large effect may be paradigmatic for therapeutic target discovery10.
To address whether additional such examples can be readily identified, we sequenced the 
exomes of 3,223 individuals from the Jackson Heart Study (JHS), a prospective cohort of 
African Americans living in Jackson, Mississippi, and catalogued null as well as damaging 
missense mutations across 18,465 genes. Subsequently, we performed an association study 
of these variants with a range of quantitative and qualitative cardiovascular traits.
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The JHS is a community-based longitudinal cohort study located in the Jackson, Mississippi 
metropolitan area designed to investigate the determinants of cardiovascular disease in 
African Americans11. JHS recruited 5,301 African Americans, aged between 35–84, 
between September 2000 and March 200811. The Institutional Review Board of the 
University of Mississippi Medical Center approved the study protocol and all participants 
provided written informed consent.
Exome Sequencing
Exome sequencing was performed at three sequencing centers (the Broad Institute [n = 
2,317], University of Washington [n = 481], and Baylor University [n = 475]) across 5 
projects (The U.S. National Heart, Lung, and Blood Institute’s [NHLBI] Exome Sequencing 
Project [ESP], Myocardial Infarction Genetics Consortium Exome Sequencing Project 
[MIGen ExS], CHARGE-S, Type 2 Diabetes Genetic Exploration by Next-generation 
sequencing in multi-Ethnic Samples [T2D-GENES], and Minority Health Genomics and 
Translational Research Bio-Repository Database [MH-GRID]) (Supplemental Table 1). The 
sequencing reads (i.e. fastq files) from exomes were aligned to the human genome reference 
(hg19) using bwa on a per lane basis and bam files were obtained from the three sequencing 
centers. The Genome Analysis Toolkit (GATK) v3.1 HaplotypeCaller algorithm was used 
for joint variant discovery and genotyping on both exomes and flanking 50bp of intronic 
sequence (http://www.broadinstitute.org/gatk/guide/article?id=3893). Single-sample gVCFs 
were created using the GATK HaplotypeCaller with the options -emitRefConfidence GVCF, 
--variant_index_type LINEAR, and --variant_index_parameter 128000. Then batches of 
~200 gVCFs were merged into a single gVCF using the CombineGVCF command in 
GATK. Finally, GenotypeGVCFs was run on the combined gVCFs to create the raw SNP 
and indel VCFs. As a majority of individuals were sequenced at the Broad Institute, we 
limited analysis to the sequence intervals captured by the Broad’s exome sequencing 
platform.
Variant Quality Control
GATK Variant Quality Score Recalibration (VQSR) was used with the recommended 
resources to filter variants. The SNP VQSR model was trained using HapMap3.3 and 1KG 
Omni 2.5 SNP sites and a 99.5% sensitivity threshold was applied to filter variants, while the 
INDEL VQSR model was trained using the Mills 1000G gold standard and Axiom Exome 
Plus sites for insertions/deletions and a 99.0% sensitivity threshold was applied to filter 
INDEL sites. Variants were filtered to VQSR PASS and quality depth (QD) ≥ 2. 
(Supplemental Table 2). Individual genotypes were set to missing if depth < 5.
Sample Quality Control
We performed quality control on the jointly-called samples. Individuals were checked for 
total number of variants, observed number of singletons and doubletons, Ti/Tv ratio, 
Het/Hom ratio, missingness, contamination with VerifyBamID12, and non-reference 
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concordance with available genotype data from the Illumina HumanExome BeadChip v1.0. 
Individuals that were outliers (> ± 3*interquartile range) on at least one metric were 
excluded (Supplemental Table 1, Supplemental Figure 1). Population structure was assessed 
using the multi-dimensional scaling (MDS) algorithm in the PLINK software13 and ten 
principal components of ancestry were obtained (Supplemental Figure 2).
Annotation
All variant sites were annotated with the Variant Effect Predictor algorithm (VEP; http://
useast.ensembl.org/info/docs/tools/vep) and dbSFP14 (https://sites.google.com/site/jpopgen/
dbNSFP). Analysis was limited to variants predicted to be null (nonsense, splice, frameshift) 
plus missense variation predicted to be damaging in at least five of the following seven 
variation prediction tools15: LRT16, Mutation Taster17, PolyPhen218 (HumDiv), PolyPhen2 
(HumVar), SIFT19, MutationAssessor20 and FATHMM21.
Phenotypes
We analyzed 36 cardiovascular traits (Figure 1) available in the Jackson Heart Study 
Vanguard Center data package (https://www.jacksonheartstudy.org/jhsinfo/ForResearchers/
VanguardCenters/tabid/171/Default.aspx). For participants who were taking antihypertensive 
medication, we added 10 mm Hg to observed systolic blood pressure (SBP) values and 5 
mm Hg to diastolic blood pressure (DBP) values22. We adjusted the total cholesterol values 
for individuals on lipid lowering medication by replacing their total cholesterol values by 
total cholesterol divided by 0.823. No adjustment was made on high-density lipoprotein 
cholesterol (HDL-C) or triglycerides. Only fasting lipid measures were used and LDL-C was 
calculated using the Friedewald equation for those with triglycerides < 400 mg/dl, using the 
lipid adjusted total cholesterol for those on treatment.
Individuals with diabetes were excluded in analyses of fasting plasma glucose, fasting 
insulin, HOMA-IR, HOMA-B, and HbA1c. Individuals with QRS > 120, atrial fibrillation, 
or coronary heart disease were excluded for analysis of QRS interval. Individuals with QRS 
≥ 120, ECG heart rate < 40, ECG heart rate > 120, or with atrial fibrillation were excluded 
from the analysis of QT interval. Individuals with end stage renal disease (ESRD) defined as 
eGRF < 15 or reporting being on dialysis, hemoglobinopathy defined as being homozygous 
for rs334, or myelotoxic drug use were excluded from the blood cell trait analyses.
Non-normality of the following raw traits was resolved by a natural log transform before 
analysis: triglycerides, leptin, hsCRP, endothelin, renin, aldosterone, and adiponectin. Non-
normality was resolved by the log transformation.
Association Analysis
We performed gene-based analyses of 36 cardiovascular phenotypes. We limited analysis to 
null mutations plus missense variants predicted to be damaging by at least 5 of 7 in silico 
prediction algorithms (LRT, Mutation Taster, PolyPhen2 (HumDiv), PolyPhen2 (HumVar), 
SIFT, MutationAssessor and FATHMM)15. We aggregated variants with minor allele 
frequency (MAF) < 5% within each gene using four sets of variants: (1) null mutations only, 
(2) null mutations plus missense variants predicted to be damaging by 7 of 7 in silico 
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prediction algorithms, (3) null mutations plus missense variants predicted to be damaging in 
at least 6 of 7 in silico prediction algorithms, and (4) null mutations plus missense variants 
predicted to be damaging in at least 5 of 7 in silico prediction algorithms. All associations 
were performed using the EPACTS (http://genome.sph.umich.edu/wiki/EPACTS) software. 
EPACTS (Efficient and Parallelizable Association Container Toolbox) is a software pipeline 
to perform statistical tests of association using sequence data. It implements the EMMAX24 
(Efficient Mixed Model Association eXpedited) model, a mixed model association approach 
that captures pedigree, cryptic relatedness, and population structure by using a covariance 
matrix estimated from genome-wide data. To apply the EMMAX model, we used the epacts-
group command with the emmaxCMC test option to perform collapsing burden gene-based 
tests. The single command with the q.emmax test option in EPACTS was used to obtain the 
single variant results for each variant going into the gene-based test. We used an additive 
genetic model. A kinship matrix of all individuals was created with EPACTS and used in 
analyses. All analyses were adjusted for age, sex, and 4 principal components of ancestry. 
Analyses for QT interval and QRS additionally included adjustments for height and BMI.
We excluded results with ≤ 10 minor alleles contributing to the gene-based test to ensure 
robust association statistics. We set our significance threshold to 1.1 × 10−7 (0.05/[36 
traits*~12,500 genes after minor allele count exclusion]).
A Wilcoxon rank sum test was performed to compare PCSK9 null compound heterozygous 
carriers to heterozygous carriers using the R software (version 3.1). Coronary artery 
calcification (CAC) percentiles were calculated with the MESA CAC Score Reference 
Values web tool (http://www.mesa-nhlbi.org/Calcium/input.aspx)25.
Power
We performed power calculations using the Genetic Power calculator (http://
pngu.mgh.harvard.edu/~purcell/gpc/) with the “QTL association for sib-ships and 
singletons” option.
Results
After quality control, 3,223 individuals from the Jackson Heart Study were available for 
analysis (Table 1, Supplemental Table 1). We observed 17,263 null variants with MAF < 5% 
and 49,929 missense variants predicted to be damaging in at least 5 of 7 in silico prediction 
algorithms with MAF < 5% (Supplemental Table 2). Of the 18,465 genes sequenced, 14,058 
have a null or damaging missense variant with MAF < 5%. On average, we observe 5 null or 
damaging missense variants per gene and an average of 7 null or damaging missense alleles 
per gene. Each individual carries, on average, a total of 153 null or damaging missense 
variants with MAF < 5%.
We found three gene-based associations that met our pre-specified significance threshold of 
1.1 × 10−7 (Table 2, Supplemental Table 3, Supplemental Table 4). The most significant 
association was between LDL-C and PCSK9. Participants who carried null or damaging 
missense mutations in PCSK9 had 36 mg/dl lower LDL-C compared with non-carriers (p-
value=2.9 × 10−21). Of note, we identified three individuals with complete PCSK9 
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deficiency (each compound heterozygote for PCSK9 p.Y142X and p.C679X) (Table 3). 
These individuals had a lower median LDL-C (64.2 mg/dl) compared to individuals that 
carry only one null mutation (85.7 mg/dl; n=77) (p-value=0.044; Supplemental Figure 3). 
The three PCSK9 null compound heterozygotes did not differ from heterozygotes in any 
other cardiometabolic trait tested except QT interval (Supplemental Table 5). Compound 
heterozygotes had a lower QT interval (mean=369, range=362–380) compared to individuals 
that carried only one null PCSK9 variant (mean=413) (p-value=0.006 using a Wilcoxon rank 
sum test). Individuals carrying one null PCSK9 variant had similar QT intervals compared 
with non-carriers (mean=413), suggesting a recessive effect. Two individuals carrying both 
PCSK9 p.Y142X and p.679X had a coronary artery calcification (CAC) greater than the 
80th-percentile for their age and sex. A 52-year-old man had a CAC of 24.9, which is in the 
83rd-percentile for age and sex, despite an LDL-C of 32 mg/dl (Table 3).
The second most significant gene association was between mean corpuscular hemoglobin 
(MCH) and hemoglobin subunit theta 1 (HBQ1). Individuals carrying a damaging missense 
variant (p.G52A)26 in HBQ1 had lower MCH compared with non-carriers (p-value=8.4 × 
10−13). One additional association passed our significance threshold. Rare damaging 
missense variants in Vacuolar Protein Sorting-Associated Protein 13A (VPS13A) were 
associated with an increase in red blood cell distribution width (p-value=7.1 × 10−8). Of the 
nine variants that contributed to the association between VPS13A and red blood cell 
distribution width, six were singletons, one a doubleton, one with four carriers (p.S2673L) 
and one with 22 minor allele carriers (p.K2672N) (Supplemental Table 4). VPS13A showed 
evidence for association with other hematologic phenotypes, including lower hemoglobin 
levels (p-value=7.0 × 10−04; Supplemental Table 6).
Li et al27 recently reported ten gene-based associations aggregating null variants with a p-
value < 4.4 × 10−6. Individuals of African Ancestry contributed to seven of these 
associations. We attempted to replicate these seven associations in our data (Supplemental 
Table 7). We replicated the association of total cholesterol with PCSK9 (beta = -39 mg/dl; p-
value = 6.6 × 10−12), and of triglycerides with apolipoprotein C-III (APOC3; p-value = 1.0 × 
10−5)2, 28–30. We found suggestive evidence for the association of fasting glucose with 
thioredoxin domain containing 5 (TXNDC5), consistent with the report by Li et al; carriers 
of null alleles in TXNDC5 had higher fasting glucose compared with non-carriers (p=0.07).
For 3,223 individuals and a significance level of 1.1 × 10−7, we had 99% statistical power to 
detect a 1-standard deviation unit effect with a 1% cumulative minor allele frequency, and 
64% statistical power to detect a 1-standard deviation unit effect with a 0.5% cumulative 
minor allele frequency. Analysis of Mendelian lipid genes as a ‘positive control’ shows 
several genes where a burden of null/damaging mutations alters the expected plasma lipid 
fraction in the appropriate direction (e.g., LDLR and higher LDL-C [P=4.7 × 10−5], CETP 
and higher HDL-C [P=0.0001]) (Supplemental Table 8). However, even an analysis of 
positive controls is limited by the number of carriers, with the majority of the Mendelian 
lipid genes having < 10 observed null alleles.
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We set out to discover null or damaging missense variants that lead to a large effect on any 
of a range of cardiovascular traits. In a study of 3,223 African Americans, we found three 
associations that met our pre-specific significance threshold.
We report one new observation, that of VPS13A associated with an increase in red blood cell 
distribution width (RDW). RDW is a measure of the range of variation in red blood cells and 
higher values can indicate certain disorders such as anemia. Mutations in VPS13A have 
been reported to cause chorea-acanthocytosis, an autosomal recessive neurodegenerative 
disorder that causes red blood cells to appear spiky31. Ten VPS13A variants are reported in 
ClinVar with chorea-acanthocytosis listed as the condition. We did not find any of the 
reported ClinVar variants in our data nor any carriers of rare damaging recessive variants in 
VPS13A. Here, in a sample of individuals unselected for disease state, we report a milder 
phenotype resulting from heterozygous mutations in VPS13A. Similar to VPS13A, 
Mendelian lipid genes having a large effect on plasma lipid levels have been shown to harbor 
common variants with smaller effects on phenotype32–34.
We found three individuals who are compound heterozygous for null mutations in PCSK9. 
Previously, only two individuals with PCSK9 deficiency have been reported35, 36. Both of 
the previously reported individuals were young (21 and 31 years old) and had very low 
circulating LDL-C (14–16 mg/dl). The three individuals we have identified here are older 
(50–52 years old) and have higher circulating LDL-C (32–72 mg/dl). One of the three 
individuals had a CAC score in the 83rd-percentile despite a LDL-C of 32 mg/dl. CAC 
values over the 75th-percentile are considered abnormal.
Some limitations deserve mention. The association between VPS13A and RDW needs to be 
confirmed in an independent study. Furthermore, sequencing will be required for replication; 
none of the variants driving the novel gene-based association were available on the widely-
used exome genotyping array. The few results passing our pre-specified significance level 
could be explained by statistical power given our sample size and the limited number of 
observed null alleles per gene. We also note that we have used a stringent significance 
threshold given the multiple testing burden inherent in our study design.
In conclusion, a limited number of null/damaging alleles with a large effect on 
cardiovascular traits were detectable from the exome sequences of 3,000 African American 
individuals.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The correlation of null alleles with human phenotypes can provide insight into gene 
function in humans. Here, we performed whole exome sequencing in 3,223 African 
American individuals living in Jackson, Mississippi in order to identify null and 
damaging missense variants and test these variants for association with 36 cardiovascular 
traits. We replicated the association of null and damaging missense variants in PCSK9 
with LDL cholesterol and found three individuals in their 50s each compound 
heterozygous for PCSK9. Of note, one of these three individuals had a coronary artery 
calcification score in the 83rd-percentile despite a LDL-C of 32 mg/dl. We also found 
individuals with rare damaging missense variants in VPS13A had higher red blood cell 
distribution width compared with non-carriers. Mutations in VPS13A have been 
previously reported to cause chorea-acanthocytosis, an autosomal recessive 
neurodegenerative disorder that causes red blood cells to appear spiky. Only a limited 
number of null/damaging alleles with a large effect on cardiovascular traits were 
detectable in ~3,000 African American individuals.
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Cardiovascular traits tested for association with null and damaging missense variants. 36 
cardiovascular traits were tested for association with null and damaging missense variants in 
3,223 African American individuals from the Jackson Heart Study.
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Table 1
Descriptive statistics of Jackson Heart Study participants with exome sequences. Statistic provided as mean
±standard deviation for continuous variables and n (percent) for categorical variables.
Trait N Statistic
Demographic
Female 3223 1211 (37.6%)
Age (years) 3223 55.59±12.82
Current Smoking status 3195 428 (13.4%)
Anthropometrics
Body Mass Index [BMI] (kg/m2) 3216 31.99±7.37
Weight (kg) 3218 91.37±21.71
Height (cm) 3218 169.06±9.25
Waist Circumference (cm) 3216 101.36±16.26
Neck Circumference (cm) 3219 38.72±3.76
Hypertension
Hypertension, Yes [HTN] 3223 2012 (62.4%)
Systolic Blood Pressure [SBP] (mmHg)* 3217 132.11±19.87
Diastolic Blood Pressure [DBP] (mmHg)* 3217 81.50±10.80
Anti-hypertensive treatment 2619 1655 (63.2%)
Lipids
LDL-C† (mg/dl) 2950 131.8±39.29
HDL-C (mg/dl) 2980 51.58±14.76
Triglycerides (mg/dl) 2979 107.61±82.77
Total Cholesterol† (mg/dl) 2395 206.08±43.44
Lipid-Lowering Treatment 2619 367 (14%)
Coronary Heart Disease
Coronary Heart Disease Status [CHD] 3223 251 (7.8%)
Coronary Artery Calcium Score [CAC] (Agatston units) 1795 176.93±550.8
CAC>0 1795 882 (49.1%)
CAC>100 1795 439 (24.5%)
Diabetes
Diabetic Status 3220 745 (23.1%)
Fasting Insulin (Plasma IU/mL)‡ 2388 15.88±9.22
HOMA-B‡ (mmol/l) 2357 215.75±107.75
HOMA-IR‡ (mmol/l) 2386 3.59±2.29
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Trait N Statistic
Fasting Plasma Glucose Level (mg/dL)‡ 2390 90.53±8.97
Hemoglobin HbA1c (%)‡ 2429 5.51±0.47
Biomarkers
Leptin (Serum ng/mL) 3198 28.39±23.98
High Sensitivity C-Reactive Protein [hsCRP] (Serum mg/dL) 3214 0.53±1
Endothelin-1 (Serum pg/mL) 3214 1.34±0.6
Aldosterone (Serum ng/dL) 3213 5.81±4.92
Renin Activity RIA (Plasma ng/mL/hr) 1509 1.72±6.45
Cortisol Levels (Serum ug/dL) 3213 9.87±4.13
Adiponectin (Plasma ng/mL) 3166 5345.18±4236.78
Electrocardiogram
QT Interval (msec) 3008 413.34±30.74
QRS Interval (msec) 2802 92.08±9.95
Blood
Hematocrit level (%) 3110 39.27±4.2
Hemoglobin (g/dl) 3109 13.04±1.48
Mean corpuscular hemoglobin [MCH] (pg) 2781 28.88±2.51
Mean corpuscular hemoglobin concentration [MCHC] (%) 2781 33.16±0.91
Mean corpuscular volume [MCV] (fL) 2781 86.97±6.41
Red blood cell distribution width [RDW] (%) 2780 13.70±1.38
Red cell count (m/cmm) 2781 4.53±0.51
*
Values were adjusted for individuals on blood pressure lowering medication.
†
Values were adjusted for individuals on lipid lowering medication.
‡
Values for non-diabetic individuals
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Table 3
Phenotypes of compound heterozygotes for PCSK9 null mutations.
Trait Individual 1 Individual 2 Individual 3
Demographic
Sex Female Female Male
Age (years) 50 50 52
Current Smoker Yes No Yes
Anthropometrics
Body Mass Index [BMI] (kg/m2) 23.7 36.7 28.3
Weight (kg) 60.6 95.2 84.6
Height (cm) 160 161 173
Waist Circumference (cm) 82 118 96
Neck Circumference (cm) 34 36 40
Hypertension
Hypertension, Yes [HTN] No Yes Yes
Systolic Blood Pressure [SBP] (mmHg)* 96 140 166
Diastolic Blood Pressure [DBP] (mmHg)* 64 84 105
Anti-hypertensive treatment No Yes No
Lipids
LDL-C (mg/dl) 71.6 64.2 32
HDL-C (mg/dl) 63 98 41
Triglycerides (mg/dl) 97 34 142
Total Cholesterol (mg/dl) 154 169 101
Lipid-lowering Treatment No No Not reported
Coronary Heart Disease
Coronary Heart Disease Status [CHD] No No No
Coronary Artery Calcium Score [CAC] 2.7 0 24.9
CAC percentile 87th 0th 83rd
Diabetes
Diabetic Status Yes No No
Fasting Insulin (Plasma IU/mL) 17 12 13
HOMA-B (mmol/l) 194.4 200.6 139.9
HOMA-IR (mmol/l) 4.0 2.5 3.1
Fasting Plasma Glucose Level (mg/dL) 95 85 97
Hemoglobin HbA1c (%) 6.3 5.4 5.4
Biomarkers
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Trait Individual 1 Individual 2 Individual 3
Leptin (Serum ng/mL) 13.8 55.3 12.9
High Sensitivity C-Reactive Protein [hsCRP] (Serum mg/dL) 0.1 6.4 0.2
Endothelin-1 (Serum pg/mL) 1.4 1.5 3
Aldosterone (Serum ng/dL) 4.6 1.9 5.6
Renin Activity RIA (Plasma ng/mL/hr) 1.3 1.4 0.3
Cortisol Levels (Serum ug/dL) 6.2 12.2 8.8
Adiponectin (Plasma ng/mL) 2585.5 4847.6 3184.3
Electrocardiogram
QT Interval (msec) 366 362 380
QRS Interval (msec) 84 102 114
Blood
Hematocrit level (%) 41.1 38.7 47.8
Hemoglobin (g/dl) 13.8 13.2 15.3
Mean corpuscular hemoglobin [MCH] (pg) 30.6 30.3 27
Mean corpuscular hemoglobin concentration [MCHC] (%) 33.7 34.2 32
Mean corpuscular volume [MCV] (fL) 90.8 88.5 84.4
Red blood cell distribution width [RDW] (%) 13.2 14.3 13.4
Red cell count (m/cmm) 4.5 4.4 5.7
*
Values were adjusted for individuals on blood pressure lowering medication.
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